

Chromosome Band 7q22 in Myeloid Leukemias

By Konstanze Fischer, Stefan Fröhling, Stephen W. Scherer, Jill McAllister Brown, Claudia Scholl, Stephan Stilgenbauer, Lap-Chee Tsui, Peter Lichter, and Hartmut Döhner

Loss of chromosome 7 (–7) or deletion of its long arm (7q–) are recurring chromosome abnormalities in myeloid disorders, especially in therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML). The association of –7/7q– with myeloid leukemia suggests that these regions contain a novel tumor suppressor gene(s) whose loss of function contributes to leukemic transformation or tumor progression. Based on chromosome banding analysis, two critical regions have been identified: one in band 7q22 and a second in bands 7q32–q35. We analyzed bone marrow and blood samples from 21 patients with myeloid leukemia (chronic myeloid leukemia, n = 2; de novo MDS, n = 4; de novo AML, n = 13; t-AML, n = 2) that on chromosome banding analysis exhibited deletions (n = 19) or reciprocal translocations (n = 2) of band 7q22 using fluorescence in situ hybridization. As probes, we used Alu-polymerase chain reaction products from 22 yeast artificial chromosome (YAC) clones that span chromosome bands 7q21.1–q32, including representative clones from a panel of

YACs recognizing a contiguous genomic DNA fragment of 5 to 6 Mb in band 7q22. In the 19 cases with deletions, we identified two distinct commonly deleted regions: one region within band 7q22 was defined by the two CML cases; the second region encompassed a distal part of band 7q22 and the entire band 7q31 and was defined by the MDS/AML cases. The breakpoint of one of the reciprocal translocations was mapped to 7q21.3, which is centromeric to both of the commonly deleted regions. The breakpoint of the second translocation, which was present in unstimulated bone marrow and phytohemagglutinin-stimulated blood of an MDS patient, was localized to a 400-kb genomic segment in 7q22 within the deletion cluster of the MDS/AML cases. In conclusion, our data show marked heterogeneity of 7q22 deletion and translocation breakpoints in myeloid leukemias, suggesting the existence of more than one pathogenetically relevant gene.

© 1997 by The American Society of Hematology.

LOSS OF CHROMOSOME 7 (–7) or deletion of its long arm (7q–) are recurring chromosome abnormalities in myeloid disorders. These aberrations are associated with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), in particular with therapy-related MDS/AML (t-MDS/t-AML) after therapy with alkylating agents or secondary MDS/AML after occupational exposure to chemical mutagens.^{1–3} Furthermore, –7/7q– occur in MDS and AML that develop in patients with constitutional disorders (eg, Fanconi's anemia, Kostmann's syndrome, neurofibromatosis type 1, and familial monosomy 7).⁴ Clinically, myeloid leukemias exhibiting –7/7q– are associated with high susceptibility to infections, poor response to chemotherapy, and short survival times.^{1,5}

Based on chromosome banding analysis, there appear to be two critical regions on the long arm of chromosome 7: one in band 7q22 and a second in bands 7q32–q35.^{3,6–9} The recurrent loss of chromosome material suggests that these

regions contain a novel tumor suppressor gene(s) whose loss of function leads to leukemic transformation. At present, there are scarce data on the molecular characterization of the genomic region affected by these deletions. No tumor suppressor gene of pathogenic significance has been identified. Kere et al^{10,11} studied 4 patients with myeloid disorders exhibiting partial 7q deletions. Using restriction fragment length polymorphism (RFLP) and quantitative Southern blot analysis, they localized the proximal breakpoints of all 4 cases between the genes for erythropoietin (EPO) and plasminogen activator inhibitor 1 (*PLA1H1*).¹⁰ All deletions were interstitial, with variability of the distal breakpoints.¹¹ In another RFLP study of 5 patients with myeloid disorders and 7q deletions, all 5 deletions were interstitial, with great variability of the proximal and distal breakpoints.¹² However, in these studies, the resolution of the deletion map was limited because the applied probes were scattered along a large genomic region.

Recently, fluorescence in situ hybridization (FISH) with mapped cosmid and yeast artificial chromosome (YAC) clones has been used for the molecular analysis of chromosome 7 aberrations.^{9,13} Johnson et al¹³ defined a small genomic region in a patient carrying a constitutional inversion inv(7)(q22.1q34) and in an unrelated patient with a translocation t(2;7)(p11;q21.2) who both had developed MDS. The breakpoints of both the inversion and the translocation were localized to a 650-kb genomic fragment in band 7q22.1. In a series of 15 patients with myeloid or lymphoid malignancies, Le Beau et al⁹ recently described a 2- to 3-Mb commonly deleted region in band 7q22 that is located distally to the inversion breakpoint described by Johnson et al.¹³

In the present study, we characterized deletions and translocations affecting chromosome band 7q22 in 21 patients with myeloid leukemias using FISH. As probes, we selected 22 clones from a contig map of YAC clones encompassing bands 7q21.1–q32.^{14–17} Because overlapping YAC clones

From the Medizinische Klinik and Poliklinik V, University of Heidelberg, Heidelberg, Germany; the Department of Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada; and Abteilung "Organisation komplexer Genome", Deutsches Krebsforschungszentrum, Heidelberg, Germany.

Submitted August 9, 1996; accepted October 23, 1996.

Supported by grants from the Deutsche Forschungsgemeinschaft (Do436/3-2), the European Community (GENE-CT 930055), and the Canadian Genome Analysis and Technology Program (CGAT).

Address reprint requests to Hartmut Döhner, MD, Medizinische Klinik and Poliklinik V, University of Heidelberg, Hospitalstraße 3, 69115 Heidelberg, Germany.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1997 by The American Society of Hematology.

0006-4971/97/8906-0036\$3.00/0

Table 1. Designation of YAC Clones, Chromosomal Localization, Size, and DNA Markers/Genes on Each YAC Clone

Name	Location	Size (kb)	DNA Markers
HSC7E520	7q21.1	500	<i>CACNL2A</i> , <i>HGF</i> , <i>D7S581</i> , <i>D7S802</i> , <i>D7S849</i> , <i>D7S2275E</i>
HSC7E590	7q21.1-q21.2	460	<i>D7S166</i> , <i>D7S195</i> , <i>D7S260</i> , <i>D7S524</i> , <i>D7S644</i> , <i>D7S2537</i>
HSC7E481	7q21.1-q21.3	900	<i>PGY1</i> , <i>PGY3</i> , <i>D7S269</i> , <i>D7S575</i> , <i>D7S1642</i> , <i>D7S1646</i> , <i>D7S2621</i> , <i>D7S2623</i> , <i>D7S2624</i> , <i>D7S2626</i> , <i>D7S2628</i> , <i>D7S2786</i> , <i>Cdy11e05</i>
HSC7E502	7q21.1-q21.3	600	<i>D7S183</i> , <i>D7S492</i> , <i>D7S569</i> , <i>D7S570</i> , <i>D7S577</i>
HSC7E465	7q21.3	700	<i>CALCR</i> , <i>D7S15</i> , <i>D7S652</i> , <i>D7S657</i> , <i>D7S2430</i> , <i>HSC7E1275RV</i>
HSC7E783	7q21.3-q22.1	650	<i>ASNS</i> , <i>D7S82</i> , <i>D7S554</i> , <i>HSC7E1131RV</i> , <i>UT901</i>
HSC7E911	7q22	580	<i>D7S651</i> , <i>NIB217</i> , <i>932D8.1</i> , <i>E911.1</i>
HSC7E808	7q22	470	<i>D7S647</i> , <i>D7S2498</i> , <i>D7S2832</i> , <i>AFMa163ya9</i> , <i>E808.3</i> , <i>CYP3A4</i>
HSC7E914	7q22	340	<i>D7S647</i> , <i>D7S2832</i> , <i>AFMa163ya9</i> , <i>CYP3A4</i>
HSC7E737	7q22	250	<i>PLANHI</i> , <i>D7S477</i> , <i>UT682</i>
HSC7E791	7q22	250	<i>CUTL1</i> , <i>D7S515</i> , <i>D7S666</i> , <i>D7S740</i> , <i>D7S2433</i> , <i>D7S2536</i>
HSC7E329	7q22	380	<i>D7S2448</i> , <i>APCR.HSC7E452</i> , <i>APCR.HSC7E570</i> , <i>942E8.18</i>
HSC7E316	7q22	440	<i>APCR.HSC7E452</i> , <i>942E8.18</i>
HSC7E441	7q22	480	<i>D7S76</i> , <i>D7S238</i> , <i>D7S561</i> , <i>D7S658</i> , <i>D7S796</i> , <i>D7S818</i> , <i>D7S2504</i>
HSC7E485	7q22	540	<i>D7S76</i> , <i>D7S238</i> , <i>D7S561</i> , <i>D7S562</i> , <i>D7S563</i> , <i>D7S796</i> , <i>D7S818</i>
HSC7E506	7q22	520	<i>D7S240</i> , <i>D7S561</i> , <i>D7S562</i> , <i>D7S563</i> , <i>D7S572</i> , <i>D7S579</i> , <i>D7S584</i> , <i>D7S2509</i>
HSC7E572	7q22.3-q31.1	400	<i>D7S1493</i> , <i>D7S1799</i> , <i>D7S2494</i>
HSC7E161	7q22.3-q31.1	450	<i>PRKAR2B</i> , <i>DRA</i> , <i>D7S496</i> , <i>D7S2317</i> , <i>D7S2459</i> , <i>Bdy96E06</i>
HSC7E132	7q22.3-q31.1	650	<i>D7S13</i> , <i>D7S1763</i> , <i>Bdy31e11</i>
HSC7E4	7q31.2-q31.3	600	<i>CAPZA2</i> , <i>MET</i> , <i>D7S567</i> , <i>D7S568</i> , <i>D7S1764</i> , <i>D7S2460</i>
HSC7E222	7q31.3-q32.1	580	<i>D7S480</i> , <i>D7S650</i> , <i>D7S685</i> , <i>D7S2821</i> , <i>CdyOrd04</i>
HSC7E1289	7q32.1	1800	<i>GRM8</i> , <i>D7S514</i> , <i>D7S680</i> , <i>D7S686</i> , <i>D7S1498</i> , <i>D7S1801</i> , <i>D7S1822</i> , <i>D7S1873</i> , <i>D7S1874</i> , <i>D7S2244</i>
HSC7E526	7q36	560	<i>D7S68</i> , <i>D7S593</i> , <i>D7S594</i>

The region between YAC clones HSC7E808 to HSC7E572 represents approximately 5 to 6 Mb of DNA and this region is covered completely by an overlapping set of YAC clones.¹⁷ HSC7E914, HSC7E737, HSC7E791, HSC7E329, HSC7E316, HSC7E441, HSC7E485, and HSC7E506 are representative clones from this contig that were chosen to be uniformly spaced throughout the region. The genes encoding *EPO* and *ACHE* are located between clones HSC7E911 and HSC7E808.²⁰ To mark the end of the chromosome, we used clone HSC7E526, which begins approximately 100 kb from the end of the chromosome and extends 560 kb towards the centromere.²⁰

were used, it was possible to systematically delineate the extent of the deletions and to locate the breakpoints of reciprocal translocations on the molecular level.

MATERIALS AND METHODS

Patients

Bone marrow and/or blood samples from 21 adult patients with myeloid disorders that on banding analysis exhibited deletions or translocations of chromosome band 7q22 were analyzed. The diagnosis were as follows: chronic-phase chronic myeloid leukemia (CML), *n* = 2 (nos. 1 and 2); de novo MDS, *n* = 4 (nos. 3 through 6); de novo AML, *n* = 13 (nos. 7 through 19); and t-AML, *n* = 2 (nos. 20 and 21). G-banding analysis was performed using standard methods. Images were captured and processed in the Ikaros system (MetaSystems, Altlußheim, Germany) and the karyotypes were designated according to the International System for Cytogenetic Nomenclature.¹⁸

DNA Probes

For the interphase and metaphase FISH experiments, we selected the following 22 YAC clones (Table 1) that were previously mapped to chromosome bands 7q21.1 to 7q32 (genes that are present on each YAC are given in parentheses): HSC7E520 (*CACNL2A*; *HGF*), HSC7E590, HSC7E481 (*PGY1*, *PGY3*), HSC7E502, HSC7E465 (*CALCR*), HSC7E783 (*ASNS*), HSC7E911, HSC7E808, HSC7E914, HSC7E737 (*PLANHI*), HSC7E791 (*CUTL1*), HSC7E329, HSC7E316, HSC7E441, HSC7E485, HSC7E506, HSC7E572, HSC7E161

(*PRKAR2B*, *DRA*), HSC7E132, HSC7E4 (*CAPZA2*, *MET*), HSC7E222, and HSC7E1289 (*GRM8*).^{14-17,19,20} Information on the YAC clones is available at <http://www.genet.sickkids.on.ca/chromosome7/>.

Human sequences from the YAC clones were generated by a polymerase chain reaction (PCR) protocol using primers directed against Alu-sequences.²¹ Amplification was performed in a 100 μ L reaction mixture containing approximately 160 ng YAC-DNA, 100 mmol/L of the four dNTPs (Boehringer Mannheim, Mannheim, Germany), 10 μ L PCR buffer (Boehringer Mannheim), and 2.0 mmol/L MgCl₂ (Boehringer Mannheim). Three Alu-PCR reactions were performed using either the primers CL1, CL2, or a combination of both (0.5 μ mol/L). The products of all three reactions were combined for the FISH experiments. The probes were labeled by nick translation with biotin-16-dUTP or digoxigenin-11-dUTP (Boehringer Mannheim).

FISH

FISH was performed as described.^{22,23} The hybridization mixture contained approximately 250 ng labeled YAC-DNA, 10 μ g Cot-1 DNA fraction (BRL/Life Technologies, Gaithersburg, MD), and 10 μ g herring sperm DNA (Boehringer Mannheim).

Interphase cytogenetic analysis was performed for deletion mapping. To monitor the hybridization efficiency, we cohybridized with a YAC clone from 7q that mapped outside the region of interest. By analogy to our previous studies on deletion analyses in B-cell chronic lymphocytic leukemia, the cut-off level was defined by the mean + 3 standard deviations (SD) of the frequency of control cells exhibiting only one fluorescence signal.^{24,25} The cut-off levels were

determined for 5 representative YACs from the YAC map (range, 4.5% to 7.6%). Signal numbers were enumerated in 200 to 300 nuclei. The breakpoints of the two balanced translocations were identified by metaphase FISH. Images were captured using a cooled CCD camera (Xillix Technologies Corp, Richmond, British Columbia, Canada).

RESULTS

G-Banding

The complete karyotypes of the 21 leukemias are given in Table 2.

CML. Both CML cases were studied at diagnosis and exhibited interstitial deletions of band 7q22 in a subclone. Case no. 1 had a proximal deletion $\text{del}(7)(\text{q}11.2\text{q}22)$ (Fig 1A). Case no. 2 had a small deletion $\text{del}(7)(\text{q}22\text{q}22)$ within band 7q22 (Fig 1B).

Table 2. Karyotypes of the 21 Myeloid Leukemias

Tumor	Karyotype
CML	
1	46,XX,t(9;22)(q34;q11)[8]/ 46,XX, del(7)(q11.2q22) ,t(9;22)(q34;q11)[7]
2	46,XY,t(9;22)(q34;q11)[7]/ 46,XX, del(7)(q22q22) ,t(9;22)(q34;q11)[3]
MDS	
3	46,XY[7]/46,XY, del(7)(q22) [3]
4	46,XX[3]/46,XX,add(6)(p21), del(7)(q22q36) [7]
5	46,XX, del(7)(q22) [10]
6*	46,XY,t(3;7)(p13;q22)[20]
De novo AML	
7	47,XY, del(7)(q22q36) ,+8[20]
8	46,XY, del(7)(q11q36) ,?t(8;19)(q24;q11),del(9)(q11q22), add(21)(p11)[5]/46,XY[15]
9	48,XY,del(3)(p21),+4,der(5)t(5;13)(q31;q12 or 14), del(7)(q22) ,-13,+22,+mar[20]
10	46,XY, del(7)(q22q32) [15]
11	50,XY,der(5)t(1;5)(p22;q13), del(7)(q22) ,+11,-13, add(16)(q2?),-21,+5mar[12]
12	47,XY,-5, del(7)(q21) ,+8,+r(11q?),-13,add(17)(p11), +mar[15]
13	45,XY,add(2)(q37),del(3)(q21),-5, del(7)(q2?1) , der(13;21)(q10;q10),-17,add(21)(p11),+r,inc[6]
14	46,XX,t(2;11)(q37;q23), del(7)(q11) [21]
15	45,Y,del(X)(p11),-2,add(3)(q2?7),add(3)(p21),del(4) (q21q31),-5, del(7)(q22q32) ,add(8)(q2?4),del(9) (p22),-13,add(16)(p13),der(17)t(2;17)(q21;p11), +mar1,+mar2[16]
16	49,XY, del(7)(q22) ,+8,t(8;16)(p11;p13),+13,+13[15]
17†	No evaluable metaphases
18	46,XX,+del(1)(p22), del(7)(q11q32 or 34) ,-13[15]
19	46,XX[7]/46,XX,t(3;7)(q28;q22)[22]
t-AML	
20	40,XY,-5,-6, add(7)(q?) ,-9,add(12)(p11or13),+13, -14,-15,-16,-16,der(?)t(?;17)(?;q21),-20,-22, +mar1,+mar2,inc[5]
21	46,XX,del(3)(q21q27), add(7)(q22) ,add(19)(p13)[15]

* Translocation found in unstimulated bone marrow and PHA-stimulated blood.

† 7q- identified by interphase cytogenetics using clone HSC7E506 (see Fischer et al²³).




Fig 1. Representative partial G-banding karyotypes. (A) CML (case no. 1) exhibiting an interstitial deletion $\text{del}(7)(\text{q}11.2\text{q}22)$. (B) CML (case no. 2) with a small interstitial deletion $\text{del}(7)(\text{q}22\text{q}22)$. Note that bands 7q21 and 7q31 are closer to each other in the deleted than in the normal chromosome 7 homolog. (C) MDS (case no. 3) with a terminal deletion $\text{del}(7)(\text{q}22)$. (D) MDS (case no. 6) exhibiting a reciprocal translocation $\text{t}(3;7)(\text{p}13;\text{q}22)$ in unstimulated bone marrow and PHA-stimulated blood.

MDS/AML. Of the 4 cases with MDS, 3 (nos. 3 through 5) had large 7q deletions; all proximal breakpoints involved band 7q22 (Fig 1C). The remaining case (no. 6) had a balanced translocation $\text{t}(3;7)(\text{p}13;\text{q}22)$ that was present in unstimulated bone marrow and phytohemagglutinin (PHA)-stimulated blood (Fig 1D). Of the 15 cases with de novo or t-AML, 14 (nos. 7 through 18, 20, and 21) had terminal or interstitial deletions that involved or encompassed band 7q22. The smallest deletions were identified in cases no. 10 [$\text{del}(7)(\text{q}22\text{q}32)$] and 15 [$\text{del}(7)(\text{q}22\text{q}32)$], the latter within a highly complex karyotype. One AML case (no. 17) had no evaluable metaphase spreads on chromosome banding analysis; in this case, the deletion was identified by interphase cytogenetics with YAC clone HSC7E506.²³ The remaining case (no. 19) had a balanced translocation $\text{t}(3;7)(\text{q}28;\text{q}22)$.

Deletion and Translocation Mapping by FISH

The results of the deletion/translocation mapping by FISH are given in Fig 2. In the 19 cases of CML, MDS, and AML containing deletions, we identified two distinct commonly deleted regions.

CML. The commonly deleted segment in the 2 CML cases extended from YAC clones HSC7E914 to HSC7E791 (Fig 2). This segment was defined by case no. 2, which on banding analysis exhibited a small interstitial deletion within band 7q22 (Fig 1B). This region, which is approximately 2 to 3 Mb in size based on the YAC contig map, contains the genes encoding *PLANHI* and *CUTLI*. To detect possible submicroscopic deletions, we subsequently screened 25 CML cases with normal chromosomes 7 on G-banding analysis by FISH with YAC clones HSC7E737 and HSC7E791 from the critical region. No additional deletions of this genomic region were detected in these cases.

MDS/AML. In the 17 MDS/AML cases that exhibited 7q22 deletions, we identified a commonly deleted segment extending from YAC clone HSC7E329 in band 7q22 to clone HSC7E1289 in band 7q32 (Fig 2). The two different commonly deleted regions, which were defined by the CML and MDS/AML cases, are separated by a 380-kb genomic fragment in 7q22 recognized by YAC clone HSC7E329. The estimated size of the region deleted in all MDS/AML cases




Fig 3. Identification of the $t(3;7)(p13;q22)$ in case no. 6 by YAC clone HSC7E572 (Cy3). Note the three red signals that originate from the normal chromosome 7 (upper left), the derivative 7 (lower left), and the derivative 3 chromosome (upper right). For the identification of chromosome 3, we cohybridized with a YAC clone (fluorescein isothiocyanate) mapping to the long arm of chromosome 3.

localized between the genes for EPO and *PLANHI* at 7q22 in 7 patients and between the genes for elastin and collagen 1 α 2 (*COL1A2*) at 7q11-q21 in another 2 patients. However, the distal boundaries of the deletions were less well characterized. The proto-oncogene *MET* at band 7q31 was deleted in all 9 cases, whereas the gene encoding the T-cell receptor β at band 7q35 was retained in 4 of the 9 cases.^{11,12}

Using FISH with a panel of mapped YAC clones from 7q, Le Beau et al⁹ recently delineated a 2- to 3-Mb commonly deleted genomic segment in band 7q22 in 15 patients with myeloid or lymphoid malignancies. This segment approximately corresponds to the genomic region identified by clones HSC7E441 through HSC7E572 that is contained within the critical region of the MDS/AML cases in our study. DNA markers common to both regions include D7S658, D7S796, D7S818, D7S2504, D7S2509, and D7S2494. Interestingly, the breakpoint of the reciprocal translocation $t(3;7)(p13;q22)$, which we identified in case no. 6, not only maps to the critical segment of our MDS/AML cases but also to the smallest overlapping deleted segment identified in the study by Le Beau et al.⁹ In this case of MDS, the translocation was present in unstimulated bone marrow and PHA-stimulated blood, indicating that the rearrangement had occurred either in an early hematopoietic precursor cell differentiating to the myeloid or lymphoid lineage or in the germline and then likely predisposed the patient to the development of MDS. This translocation breakpoint may point to a novel gene of pathogenic significance in myeloid leukemias. Translocations commonly lead to the activation of proto-oncogenes or to chimeric fusion genes of oncogenic potential. However, some translocations have been shown to be accompanied by submicroscopic deletions and have led to the identification of a genomic segment likely containing a novel tumor suppressor locus.²⁶ By

analogy, the translocation breakpoint found in our MDS case may inactivate a tumor suppressor gene, eg, by disruption of its primary structure, in particular because it occurs in a deletion cluster region.

Johnson et al¹³ reported on a narrow interval at band 7q22.1 in patients with MDS. The proximal breakpoint of a constitutional inversion $inv(7)(22.1q34)$ associated with MDS as well as the breakpoint of a reciprocal translocation $t(2;7)(p13;q22)$ in an unrelated patient with MDS were found to be contained in a genomic fragment identified by YAC clone HSC7E783 (Table 1 and Fig 2). This finding suggests that this genomic region contains a specific gene(s) associated with the development of MDS. This region, which contains the gene for the cell-cycle control enzyme *ASNS*,²⁷ maps proximally to the translocation breakpoint in case no. 6 and to the commonly deleted segments that were identified in our study and that of Le Beau et al⁹ (see Fig 2). In the same study, the breakpoints of two other balanced translocations associated with MDS were localized proximally and distally to the constitutional inversion breakpoint. In keeping with these findings, we mapped the breakpoint of another balanced translocation (case no. 19) between the segments identified by clones HSC7E481 and HSC7E502, which is proximal to the inversion breakpoint reported by Johnson et al.¹³

Taken together, the data suggest that there are multiple genes in bands 7q21-q22 that are involved in the pathogenesis of myeloid leukemias. Although the commonly deleted genomic regions are still large, the identification of inversion and translocation breakpoints provides a first step towards the cloning of these genes.

ACKNOWLEDGMENT

We gratefully acknowledge Drs U. Pascheberg, J. Mittermüller, H. Schmetzer, and B. Schlegelberger for providing leukemia specimens.

REFERENCES

1. Fourth International Workshop on Chromosomes in Leukemia 1982: Abnormalities of chromosome 7 resulting in monosomy 7 or in deletion of the long arm (7q-): Review of translocations, breakpoints and associated abnormalities. *Cancer Genet Cytogenet* 11:251, 1984
2. Mitelman F, Brandt L, Nilsson PG: Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. *Blood* 52:1229, 1978
3. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes nos. 5 and 7. *J Clin Oncol* 3:325, 1986
4. Luna-Fineman S, Shannon KM, Lange BJ: Childhood monosomy 7: Epidemiology, biology, and mechanistic implications. *Blood* 85:1985, 1995
5. Bloomfield CD, de la Chapelle A: Chromosome abnormalities in acute nonlymphocytic leukemia: Clinical and biological significance. *Semin Oncol* 14:372, 1987
6. Neuman WL, Rubin CM, Rios RB, Larson RA, Le Beau MM, Rowley JD, Vardiman JW, Schwartz JL, Farber R: Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders. *Blood* 79:1501, 1992
7. Johansson B, Mertens F, Mitelman F: Cytogenetic deletion maps of hematologic neoplasms: Circumstantial evidence for tumor suppressor loci. *Genes Chromosom Cancer* 8:205, 1993
8. Rodrigues Pereira Velloso E, Michaux L, Ferrant A, Hernandez JM, Meeus P, Dierlamm J, Criel A, Louwagie A, Verhoef G, Boogaerts M, Michaux JL, Bosly A, Mecucci C, Van den Berghe H: Deletions of the long arm of chromosome 7 in myeloid disorders: Loss of band 7q32 implies worst prognosis. *Br J Haematol* 92:574, 1996
9. Le Beau MM, Espinosa R III, Davis EM, Eisenbart JD, Larson RA, Green ED: Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. *Blood* 88:1930, 1996
10. Kere J, Ruutu T, Davies KA, Roninson IB, Watkins PC, Winqvist R, de la Chapelle A: Chromosome 7 long arm deletion in myeloid disorders: A narrow breakpoint region in 7q22 defined by molecular mapping. *Blood* 73:230, 1989
11. Kere J, Donis-Keller H, Ruutu T, de la Chapelle A: Chromosome 7 long-arm deletions in myeloid disorders: Terminal DNA sequences are commonly conserved and breakpoints vary. *Cytogenet Cell Genet* 50:226, 1989
12. Lewis S, Abrahamson G, Boulwood J, Fidler C, Potter A, Wainscoat JS: Molecular characterization of the 7q deletion in myeloid disorders. *Br J Haematol* 93:75, 1996
13. Johnson EJ, Scherer SW, Osborne L, Tsui LC, Oscier D, Mould S, Cotter FE: Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasia. *Blood* 87:3579, 1996
14. Scherer SW, Tompkins BJ, Tsui LC: A human chromosome 7-specific genomic DNA library in yeast artificial chromosomes. *Mammal Genome* 3:179, 1992
15. Kunz J, Scherer SW, Klawitz I, Soder S, Du YZ, Speich N, Kalff-Suske M, Heng HHQ, Tsui LC, Grzeschik KH: Regional localization of 725 human chromosome 7-specific yeast artificial chromosome clones. *Genomics* 22:439, 1994
16. Scherer SW, Poorkaj P, Trask B, Soder S, Allen T, Nunez M, Geshuri D, Wong E, Belloni E, Little S, Zhou L, Becker D, Kere J, Ignatius J, Niikawa N, Fukushima Y, Hasegawa T, Weissenbach J, Boncinelli E, Massa H, Tsui LC, Evans JP: Physical mapping of the split hand/split foot locus (*SHFD1*) on chromosome 7 and implication in syndromic ectrodactyly. *Hum Mol Genet* 3:1345, 1994
17. Tsui LC, Donis-Keller H, Grzeschik KH: Report of the Second International Workshop on Human Chromosome 7 Mapping 1994. *Cytogenet Cell Genet* 71:1, 1995
18. Mitelman F (ed): *ISCN (1995): An International System for Human Cytogenetic Nomenclature*. Basel, Switzerland, S. Karger, 1995
19. Takahara K, Osborne L, Elliot RW, Tsui LC, Scherer SW, Greenspan DS: Fine mapping of the human and mouse genes for the type I procollagen COOH-terminal proteinase enhancer protein. *Genomics* 31:253, 1996
20. Mackay M, Fantes J, Scherer SW, Boyle S, West K, Tsui LC, Belloni E, Lutz E, Van Heyningen V, Harnar AJ: Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: A possible contributor to the holoprosencephaly 3 phenotype. *Genomics* 37:345, 1996
21. Lengauer C, Green ED, Cremer T: Fluorescence in situ hybridization of YAC clones after ALU-PCR amplification. *Genomics* 13:286, 1992
22. Lichter P, Tang CC, Call K, Hermanson G, Evans GA, Housman D, Ward DC: High resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. *Science* 247:64, 1990
23. Fischer K, Scholl C, Sälät J, Fröhling S, Stilgenbauer S, Bentz M, Lichter P, Döhner H: Design and validation of DNA probe-sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. *Blood* 88:3962, 1996
24. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. *Blood* 85:1580, 1995
25. Stilgenbauer S, Liebisch P, James MR, Schröder M, Schlegelberger B, Fischer K, Bentz M, Lichter P, Döhner H: Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.2-q23.1 in lymphoproliferative disorders. *Proc Natl Acad Sci USA* 93:11837, 1996
26. Brown AG, Ross FM, Dunne EM, Steel CM, Weir-Thompson EM: Evidence for a new tumour suppressor locus (*DBM*) in human B-cell neoplasia telomeric to the retinoblastoma gene. *Nat Genet* 3:67, 1993
27. Heng HHQ, Shi XM, Scherer SW, Andrulis IL, Tsui LC: Refined localization of the asparaginase synthetase gene (*ASNS*) to chromosome 7, region q21.3, and characterization of the somatic cell hybrid line 4AF/106/KO15. *Cytogenet Cell Genet* 66:135, 1994



blood[®]

1997 89: 2036-2041

Molecular Cytogenetic Delineation of Deletions and Translocations Involving Chromosome Band 7q22 in Myeloid Leukemias

Konstanze Fischer, Stefan Fröhling, Stephen W. Scherer, Jill McAllister Brown, Claudia Scholl, Stephan Stilgenbauer, Lap-Chee Tsui, Peter Lichter and Hartmut Döhner

Updated information and services can be found at:

<http://www.bloodjournal.org/content/89/6/2036.full.html>

Articles on similar topics can be found in the following Blood collections

[Neoplasia](#) (4212 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>